---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-26-005416"
form_type: "8-K"
ticker: "BICX"
cik: "0001443863"
company_name: "BioCorRx Inc."
filed_at: "2026-09-04T13:53:58+00:00"
generated_at: "2026-09-04T13:58:17.480026+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# BioCorRx director Kate Beebe DeVarney resigns from board effective Aug 31, 2026

## Summary
- Kate Beebe DeVarney, Ph.D. resigned from BioCorRx board effective August 31, 2026.
- Resignation not due to any disagreement with company or subsidiary BioCorRx Pharmaceuticals.
- No replacement named in filing; board size reduced accordingly.

## SEC filing metadata
- accession: 0001477932-26-005416
- form_type: 8-K
- ticker: BICX
- cik: 0001443863
- company_name: BioCorRx Inc.
- filed_at: 2026-09-04T13:53:58+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1443863/000147793226005416/0001477932-26-005416-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1443863/000147793226005416/bicx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-26-005416
- JSON: https://secwatch.observer/filing/0001477932-26-005416.json
- Plain text: https://secwatch.observer/filing/0001477932-26-005416.txt

## Key facts
- Executive change
  Kate Beebe DeVarney resigned as member of the board of directors at BioCorRx Inc..
  - Action: resigned
  - Role: member of the board of directors
  source text: On August 31, 2026, Kate Beebe DeVarney, Ph.D. submitted her resignation from her position as a member of the board of directors (the “Board”) of BioCorRx Inc.(the “Company”), effective August 31, 2026 (the “DeVarney Resignation”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1443863/000147793226005416/0001477932-26-005416-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.